Compare Apartment Investment and Management Co (AIV) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

AIV trades at $2.66, up 0.38% on the day, with a bearish technical signal from moving averages. The company reported a net income margin of 400.05% in 2025, driven by a significant tax benefit, though revenue declined to $138.49 million. Earnings history shows mixed quarterly results, with two beats and two misses against expectations. Analyst consensus is mixed with a hold rating from two of three analysts.

The outlook is cautious due to volatile earnings and declining revenue, offset by strong profitability metrics and a dividend announcement. Key risks include inconsistent financial performance and high debt levels. Upside potential exists if the company stabilizes revenue growth and maintains improved margins.

Regeneron Pharmaceuticals (REGN) trades at $784.36, up 1.59% today, with a bullish technical signal from moving averages but overbought RSI readings. The company shows strong profitability with a net income margin of 27.86% and has beaten EPS estimates in recent quarters. However, multiple class-action lawsuits filed in August 2026 allege inadequate clinical-trial risk disclosures, creating investor uncertainty amid solid financial performance.

Outlook remains supported by earnings momentum and analyst buy ratings, but legal risks and high valuation multiples pose near-term headwinds. Investment opportunity hinges on legal resolution and sustained drug pipeline success, while risks include trial setbacks and regulatory scrutiny.